Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 15.44
LCAV's Cash to Debt is ranked higher than
88% of the 242 Companies
in the Global Medical Care industry.

( Industry Median: 0.22 vs. LCAV: 15.44 )
LCAV' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 15.44

Equity to Asset 0.45
LCAV's Equity to Asset is ranked higher than
70% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. LCAV: 0.45 )
LCAV' s 10-Year Equity to Asset Range
Min: 0.09   Max: 0.94
Current: 0.45

0.09
0.94
F-Score: 5
Z-Score: 3.51
M-Score: -1.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -2.80
LCAV's Operating margin (%) is ranked higher than
53% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 9.44 vs. LCAV: -2.80 )
LCAV' s 10-Year Operating margin (%) Range
Min: -46.25   Max: 25.43
Current: -2.8

-46.25
25.43
Net-margin (%) -1.48
LCAV's Net-margin (%) is ranked higher than
58% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 4.97 vs. LCAV: -1.48 )
LCAV' s 10-Year Net-margin (%) Range
Min: -49.38   Max: 25.2
Current: -1.48

-49.38
25.2
ROE (%) -7.15
LCAV's ROE (%) is ranked higher than
56% of the 229 Companies
in the Global Medical Care industry.

( Industry Median: 8.44 vs. LCAV: -7.15 )
LCAV' s 10-Year ROE (%) Range
Min: -341.67   Max: 34.73
Current: -7.15

-341.67
34.73
ROA (%) -3.19
LCAV's ROA (%) is ranked higher than
55% of the 237 Companies
in the Global Medical Care industry.

( Industry Median: 3.63 vs. LCAV: -3.19 )
LCAV' s 10-Year ROA (%) Range
Min: -54.12   Max: 24.72
Current: -3.19

-54.12
24.72
ROC (Joel Greenblatt) (%) -36.68
LCAV's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 235 Companies
in the Global Medical Care industry.

( Industry Median: 16.84 vs. LCAV: -36.68 )
LCAV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -146.8   Max: 135.34
Current: -36.68

-146.8
135.34
Revenue Growth (%) -3.50
LCAV's Revenue Growth (%) is ranked higher than
57% of the 200 Companies
in the Global Medical Care industry.

( Industry Median: 7.00 vs. LCAV: -3.50 )
LCAV' s 10-Year Revenue Growth (%) Range
Min: -28.7   Max: 35.2
Current: -3.5

-28.7
35.2
EPS Growth (%) -60.10
LCAV's EPS Growth (%) is ranked higher than
50% of the 153 Companies
in the Global Medical Care industry.

( Industry Median: 10.90 vs. LCAV: -60.10 )
LCAV' s 10-Year EPS Growth (%) Range
Min: -60.1   Max: 44.9
Current: -60.1

-60.1
44.9
» LCAV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

LCAV Guru Trades in Q2 2013

Jim Simons 646,404 sh (-4.82%)
» More
Q3 2013

LCAV Guru Trades in Q3 2013

Jim Simons 649,900 sh (+0.54%)
» More
Q4 2013

LCAV Guru Trades in Q4 2013

Jim Simons 634,800 sh (-2.32%)
» More
Q1 2014

LCAV Guru Trades in Q1 2014

Mario Gabelli 37,500 sh (New)
Jim Simons 664,452 sh (+4.67%)
» More
» Details

Insider Trades

Latest Guru Trades with LCAV

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-03-31 New Buy$3.71 - $5.59 $ 5.3712%37500
Julian Robertson 2013-03-31 Sold Out 0.62%$2.8 - $3.55 $ 5.3770%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.42
LCAV's P/B is ranked higher than
58% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 2.89 vs. LCAV: 5.42 )
LCAV' s 10-Year P/B Range
Min: 0.48   Max: 7.96
Current: 5.42

0.48
7.96
P/S 1.12
LCAV's P/S is ranked higher than
77% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 1.63 vs. LCAV: 1.12 )
LCAV' s 10-Year P/S Range
Min: 0.19   Max: 6.32
Current: 1.12

0.19
6.32
EV-to-EBIT -31.26
LCAV's EV-to-EBIT is ranked lower than
56% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 26.76 vs. LCAV: -31.26 )
LCAV' s 10-Year EV-to-EBIT Range
Min: 0.6   Max: 61
Current: -31.26

0.6
61
Current Ratio 2.32
LCAV's Current Ratio is ranked higher than
91% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.39 vs. LCAV: 2.32 )
LCAV' s 10-Year Current Ratio Range
Min: 0.48   Max: 10.76
Current: 2.32

0.48
10.76
Quick Ratio 2.32
LCAV's Quick Ratio is ranked higher than
92% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.24 vs. LCAV: 2.32 )
LCAV' s 10-Year Quick Ratio Range
Min: 0.44   Max: 10.76
Current: 2.32

0.44
10.76

Valuation & Return

vs
industry
vs
history
Price/Net Cash 21.48
LCAV's Price/Net Cash is ranked higher than
97% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. LCAV: 21.48 )
LCAV' s 10-Year Price/Net Cash Range
Min: 2.41   Max: 82.14
Current: 21.48

2.41
82.14
Price/Net Current Asset Value 13.09
LCAV's Price/Net Current Asset Value is ranked higher than
97% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. LCAV: 13.09 )
LCAV' s 10-Year Price/Net Current Asset Value Range
Min: 2.3   Max: 22.12
Current: 13.09

2.3
22.12
Price/Tangible Book 5.43
LCAV's Price/Tangible Book is ranked higher than
73% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 8.95 vs. LCAV: 5.43 )
LCAV' s 10-Year Price/Tangible Book Range
Min: 0.79   Max: 577.78
Current: 5.43

0.79
577.78
Price/Median PS Value 0.99
LCAV's Price/Median PS Value is ranked higher than
86% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 1.26 vs. LCAV: 0.99 )
LCAV' s 10-Year Price/Median PS Value Range
Min: 0.33   Max: 9.49
Current: 0.99

0.33
9.49
Earnings Yield (Greenblatt) 9.50
LCAV's Earnings Yield (Greenblatt) is ranked higher than
88% of the 226 Companies
in the Global Medical Care industry.

( Industry Median: 5.20 vs. LCAV: 9.50 )
LCAV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 162.5
Current: 9.5

1.6
162.5
Forward Rate of Return (Yacktman) -2.89
LCAV's Forward Rate of Return (Yacktman) is ranked higher than
56% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 10.49 vs. LCAV: -2.89 )
LCAV' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.7   Max: 83.7
Current: -2.89

-1.7
83.7

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:LCV1.Germany
LCA-Vision, Inc., is a provider of fixed-site laser vision correction services at its LasikPlus vision centers. Its vision centers provide the staff, facilities, equipment and support services for performing laser vision correction that employ advanced laser technologies to help correct nearsightedness, farsightedness and astigmatism. Its vision centers are supported by ophthalmologists and credentialed optometrists, as well as other healthcare professionals. The ophthalmologists perform the laser vision correction procedures in its vision centers, and ophthalmologists or optometrists conduct pre-procedure evaluations and post-operative follow-up care in-center. It provides two types of procedures in its vision centers namely LASIK; and PRK and Surface Ablation. It began performing LASIK, in 1996, which continues to account for the majority of the laser vision correction procedures performed in the United States. In LASIK procedures, its surgeon's uses a femtosecond laser to create a thin flap, which remains hinged to the eye. In PRK procedures, the ophthalmologist removes the thin layer of cells covering the outer surface of the cornea (the epithelium) in order to apply the excimer laser pulses directly to the surface of the cornea. Following the PRK procedure, the ophthalmologist places a bandage contact lens on the eye to protect it. Most of its patients currently receive a procedure called laser-assisted in situ keratomileusis ('LASIK'), which it began performing in the United States in 1996. As of December 31, 2012, it operated 54 LasikPlus fixed-site laser vision correction centers generally located in metropolitan markets in the United States, including two vision centers licensed to ophthalmologists who operate using its trademarks. It currently uses two suppliers for its fixed-site excimer lasers: Abbott Medical Optics ('AMO') and Alcon Inc. ('Alcon'). Its business is heavily dependent on advertising, which is subject to regulation by the Federal Trade Commission ('FTC').
» More Articles for LCAV

Headlines

Articles On GuruFocus.com
LCAVision Inc. Reports Operating Results (10-Q) Oct 26 2010 
LCAVision Inc. Reports Operating Results (10-Q) Apr 27 2010 
LCAVision Inc. Reports Operating Results (10-Q) Oct 27 2009 
A Case for LCA-Vision Inc. Oct 27 2009 
LCAVision Inc. Reports Operating Results (10-Q) Jul 28 2009 
LCAVision Inc. Reports Operating Results (10-Q) Apr 28 2009 
LoJack Corp.(LOJN) Rides High Feb 25 2009 
LCAVision Inc. (LCAV) SVP of Finance and CFO Michael J Celebrezze buys 2,800 Shares Feb 23 2009 
LCAVision Inc. (LCAV) CEO Steven C Straus buys 9,000 Shares Feb 23 2009 
11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executi Dec 25 2008 

More From Other Websites
Nasdaq stocks posting largest volume increases Jul 25 2014
LCA VISION INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... May 13 2014
LCA VISION INC Files SEC form 10-Q, Quarterly Report May 08 2014
LCA VISION INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 07 2014
LCA VISION INC Files SEC form 8-K, Other Events Apr 30 2014
LCA-Vision Reports First Quarter Financial Results Apr 30 2014
Q1 2014 LCA-Vision Earnings Release - Before Market Open Apr 29 2014
LCA-Vision Announces ISS and Glass, Lewis Recommend Stockholders Vote in Favor of $5.37 per share... Apr 23 2014
LCA VISION INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 23 2014
LCA-Vision Reports First Quarter Procedure Volume of 14,898 Apr 02 2014
LCA VISION INC Financials Mar 18 2014
LCA VISION INC Files SEC form 10-K, Annual Report Mar 12 2014
INVESTOR ALERT: LEVI & KORSINSKY, LLP Notifies Investors of LCA-VISION INC. of Class Action Against... Feb 24 2014
INVESTOR ALERT – LCA-VISION INC.: The Law Offices of Vincent Wong Investigates the Sale of... Feb 21 2014
Lifshitz & Miller Law Firm Announces Investigation of Cadence Pharmaceuticals, Inc., Chindex... Feb 19 2014
INVESTOR ALERT – LCA-VISION INC.: The Law Offices of Vincent Wong Investigates the Sale of... Feb 19 2014
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of LCA-Vision, Inc.... Feb 18 2014
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of LCA-VISION INC. and Its Board of... Feb 18 2014
Ryan & Maniskas, LLP Announces Investigation of LCA-Vision Inc. Feb 18 2014
LCA-Vision Fourth Quarter 2013 Results Feature 2% Revenue Growth Feb 18 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide